๐Ÿ”ฌ Creatinine & Determinants of GFR

Glomerular Hemodynamics, Creatinine Handling, and eGFR Limitations

Visual reference

The Chemistry Panel: Read Kidney Function in Context visual summary. Open for the full image and text version.
The Chemistry Panel: Read Kidney Function in Context: full graphic and text version

Browse the visual reference library ยท Download lesson Markdown

SGLT2 Inhibitors, Loop Diuretics, and the Macula Densa

Side-by-side comparison: SGLT2 inhibition reduces proximal sodiumโ€“glucose reabsorption and increases NaCl delivery to an intact macula-densa NKCC2 sensor. ATP and adenosine signaling can constrict the afferent arteriole and lower glomerular pressure. Loop diuretics block NKCC2 in the thick ascending limb and at the sensor, blunting this feedback and favoring renin release. Net GFR also depends on perfusion, volume, and congestion.
Salt delivery is not the same as salt sensing. Trace each drug from its tubular target to the sensor and then to the glomerulus. Open full-size image ยท Use the discussion questions ยท Visual library: diagram and teaching text

Read the complete explanation and evidence โ†’

๐ŸŽฏ Why This Lecture Matters

Serum creatinine is the single most frequently used biomarker in clinical medicine to assess kidney function. Yet it is profoundly misunderstood.

Most changes in creatinine reflect changes in GFR.
The dominant clinical reality โ€” and the basis for eGFR equations.
But some changes in creatinine are NOT caused by GFR changes.
Drugs, diet, muscle mass, and tubular handling can all change creatinine independent of filtration.
In AKI, the rate of rise of creatinine is disconnected from GFR.
A concept explored in our AKI module that has profound clinical implications.

๐Ÿ”ฌ Interactive Glomerular Hemodynamics

Explore how arteriolar tone, drug effects, and glomerular pressure determine GFR and albuminuria. Click the condition buttons on the right panel to interact.

Return to the opening lecture: creatinine and kidney function โ†’

๐Ÿ“ The Determinants of GFR

GFR is governed by the Starling forces across the glomerular capillary wall. The fundamental equation is:

GFR = Kf ร— PUF

GFR = Kf ร— (PGC โˆ’ PBS โˆ’ ฯ€GC)

Where PUF = net ultrafiltration pressure

Kf โ€” Ultrafiltration Coefficient

Product of capillary surface area and hydraulic permeability.

  • Surface area regulated by mesangial cells โ€” contraction reduces Kf
  • Permeability determined by the 3-layer filtration barrier: fenestrated endothelium โ†’ GBM โ†’ podocyte slit diaphragms
  • Diseases that destroy glomeruli (e.g., GN, DKD) reduce Kf
  • Mesangial contraction by Angiotensin II, endothelin โ†’ โ†“Kf

PGC โ€” Glomerular Capillary Pressure

The dominant driving force for filtration. ~60 mmHg normally.

  • Afferent arteriolar dilation โ†’ โ†‘PGC (more inflow)
  • Efferent arteriolar constriction (Ang II) โ†’ โ†‘PGC (backs up pressure)
  • Afferent constriction (NSAIDs, SGLT2i via TGF) โ†’ โ†“PGC
  • Efferent dilation (ACEi/ARB) โ†’ โ†“PGC
  • Systemic hypotension below autoregulatory range โ†’ โ†“PGC

PBS โ€” Bowman's Space Pressure

Opposes filtration. Normally ~15 mmHg.

  • Elevated in urinary obstruction (BPH, stones, tumors)
  • Tubular obstruction (cast nephropathy, crystal nephropathy)
  • Interstitial edema compressing tubules
  • Rarely significant unless obstruction is present

ฯ€GC โ€” Glomerular Oncotic Pressure

Opposes filtration. Rises along the capillary length.

  • At afferent end: ~25 mmHg (plasma protein concentration)
  • As filtrate leaves, protein concentrates in remaining plasma
  • At efferent end: may reach ~35 mmHg โ†’ filtration equilibrium
  • Hypoalbuminemia (nephrotic syndrome, liver failure) โ†’ โ†“ฯ€GC โ†’ may increase GFR transiently but does not increase net filtration long-term due to compensatory mechanisms
  • Filtration fraction (FF) = GFR/RPF โ€” higher FF means more rapid rise in oncotic pressure along the capillary

๐ŸŽ›๏ธ Arteriolar Tone: The Master Controller of GFR

The afferent and efferent arterioles are the principal regulators of glomerular hemodynamics. Understanding their independent effects is the key to understanding drug effects on GFR.

Change RBF PGC GFR FF Clinical Example
Afferent Dilation โ†‘โ†‘ โ†‘ โ†‘ โ†“ or โ†’ Prostaglandins (PGEโ‚‚/PGIโ‚‚), early DKD
Afferent Constriction โ†“โ†“ โ†“ โ†“ โ†’ NSAIDs, SGLT2i (via TGF), cyclosporine
Efferent Constriction โ†“ โ†‘ โ†‘ (mild) โ†‘โ†‘ Angiotensin II
Efferent Dilation โ†‘ โ†“ โ†“ โ†“ ACEi/ARB (block Ang II)
Afferent Constriction + Efferent Dilation โ†“โ†“ โ†“โ†“โ†“ โ†“โ†“โ†“ โ†“ Triple Whammy: NSAID + ACEi/ARB + Diuretic

โš ๏ธ The "Triple Whammy" โ€” A Predictable Catastrophe

NSAID (afferent constriction) + ACEi/ARB (efferent dilation) ยฑ Diuretic (volume depletion) โ†’ catastrophic loss of glomerular capillary pressure.

Teaching point: This is hemodynamic AKI โ€” entirely predictable from first principles. Explore this in the interactive graphic above by selecting "NSAID + ARB (Triple Whammy)."

๐Ÿ›ก๏ธ Renal Autoregulation

The kidney maintains GFR across a wide range of systemic blood pressures through two mechanisms:

1. Myogenic Response

Afferent arteriolar smooth muscle contracts in response to increased intraluminal pressure (Bayliss effect).

  • Rapid response (seconds)
  • Intrinsic vascular smooth muscle property
  • Protects glomerulus from hypertensive injury
  • Impaired in diabetes โ†’ permits barotrauma โ†’ hyperfiltration injury

2. Tubuloglomerular Feedback (TGF)

The macula densa of the JGA senses NaCl delivery to the distal tubule and adjusts afferent arteriolar tone.

  • โ†‘NaCl delivery โ†’ adenosine release โ†’ afferent constriction โ†’ โ†“GFR
  • โ†“NaCl delivery โ†’ โ†“adenosine โ†’ afferent dilation โ†’ โ†‘GFR
  • Also modulates renin release from JGA granular cells
  • SGLT2 inhibitors restore TGF: by blocking proximal Na/glucose reabsorption โ†’ โ†‘NaCl at macula densa โ†’ afferent constriction โ†’ โ†“PGC โ†’ nephroprotection

๐Ÿ“Š Autoregulatory Range

GFR remains relatively constant between MAP of ~80โ€“180 mmHg. Below this range, GFR falls linearly with pressure. NSAIDs and calcineurin inhibitors impair autoregulation, making the kidney more vulnerable to hypotension.

In CKD, the autoregulatory curve shifts rightward โ€” patients become "dependent" on higher perfusion pressures and are more vulnerable to hypotension-induced AKI.

๐Ÿ”ฅ Hyperfiltration โ€” When GFR Is Too High

Paradoxically, an elevated GFR is one of the earliest markers of progressive kidney disease. This is the physiology that drives diabetic kidney disease.

Mechanism in Diabetes (Early DKD)

  1. Hyperglycemia โ†’ โ†‘proximal tubular glucose/Na reabsorption via SGLT2
  2. โ†“NaCl delivery to macula densa โ†’ TGF interprets this as "low GFR"
  3. TGF response: afferent dilation + Ang II-mediated efferent constriction
  4. Result: markedly elevated PGC (~78 mmHg vs normal 60 mmHg)
  5. High PGC โ†’ elevated shear stress โ†’ podocyte injury
  6. Podocyte foot process effacement โ†’ slit diaphragm widening โ†’ albuminuria
  7. Tubular exposure to filtered albumin โ†’ tubular injury โ†’ interstitial fibrosis

โœ… Therapeutic Targets

Modern nephroprotection directly targets glomerular hemodynamics:

  • ACEi/ARB: Efferent dilation โ†’ โ†“PGC โ†’ โ†“albuminuria 40โ€“50%
  • SGLT2i: Restores TGF โ†’ afferent constriction โ†’ โ†“PGC โ†’ โ†“albuminuria 30โ€“40%
  • Finerenone (MRA): Anti-fibrotic + anti-inflammatory โ†’ โ†“albuminuria 30%
  • GLP-1 RA: Additional nephroprotection via hemodynamic and metabolic pathways

The initial GFR "dip" seen with ACEi/ARBs and SGLT2i is hemodynamic (reducing PGC) and is a sign of nephroprotection, not injury โ€” as long as it is modest (<30%) and stabilizes.

๐Ÿงฌ The Three Fates of Creatinine

Creatinine is a 113-dalton molecule produced from the non-enzymatic degradation of creatine and phosphocreatine in skeletal muscle at a nearly constant rate (~20 mg/kg/day). It is handled by the kidney in three ways:

1๏ธโƒฃ Glomerular Filtration (~85โ€“90%)

Creatinine is freely filtered at the glomerulus โ€” it is small (113 Da), not protein-bound, and not charged. This is why it serves as a GFR marker. At steady state, the amount filtered โ‰ˆ the amount excreted.

This is the dominant pathway and is the basis for all eGFR equations.

2๏ธโƒฃ Tubular Secretion (~10โ€“15%)

Creatinine is actively secreted by the proximal tubule via the organic cation transporter 2 (OCT2) on the basolateral membrane, and MATE1/MATE2-K on the apical membrane.

Because of secretion, creatinine clearance (CrCl) overestimates true GFR by ~10โ€“15%. This becomes proportionally more significant as GFR falls.

3๏ธโƒฃ Tubular Reabsorption (minimal in health)

Under normal conditions, creatinine reabsorption is negligible. However, at very low urine flow rates (severe dehydration, prerenal states), back-diffusion of creatinine from the tubular lumen into peritubular capillaries can occur.

This is why CrCl may falsely underestimate GFR in severely volume-depleted patients โ€” more creatinine leaks back.

๐Ÿ“Š Why This Matters Clinically

At normal GFR, tubular secretion contributes ~10โ€“15% of total creatinine excretion, so CrCl only slightly overestimates GFR. But as GFR declines in CKD, tubular secretion becomes a proportionally larger share of total creatinine clearance โ€” meaning CrCl may overestimate true GFR by 50% or more in advanced CKD. This is one reason eGFR equations were developed to replace CrCl.

๐Ÿ’Š Drugs That Raise Creatinine WITHOUT Changing GFR

These medications inhibit tubular secretion of creatinine at OCT2 or MATE transporters, causing serum creatinine to rise even though GFR is unchanged. This is a pseudo-AKI that must be recognized.

Drug Brand/Class Mechanism Expected ฮ”Cr Clinical Pearl
Trimethoprim Bactrim (TMP-SMX) Blocks OCT2 and MATE1 โ†’ inhibits Cr secretion โ†‘ 0.2โ€“0.5 mg/dL Most common clinical scenario. Dose-dependent. Reversible on discontinuation.
Cimetidine Tagamet (H2 blocker) Competitive inhibitor of OCT2 โ†’ blocks Cr secretion โ†‘ 0.2โ€“0.4 mg/dL Historically used therapeutically to block Cr secretion when measuring CrCl to better approximate true GFR.
Triamterene Dyrenium (K-sparing diuretic) Inhibits tubular Cr secretion โ†‘ 0.1โ€“0.3 mg/dL Less commonly used today. Also seen with amiloride to lesser degree.
Dolutegravir Tivicay (INSTI for HIV) Inhibits OCT2 โ†’ blocks Cr secretion โ†‘ 0.1โ€“0.2 mg/dL Consistent effect seen in clinical trials. Occurs within first 2โ€“4 weeks and stabilizes. GFR unaffected.
Cobicistat CYP3A4 booster (HIV regimens) Inhibits MATE1 โ†’ blocks Cr secretion โ†‘ 0.1โ€“0.3 mg/dL Seen with all cobicistat-containing HIV regimens. Predictable, stable rise.
Dronedarone Multaq (antiarrhythmic) Inhibits tubular Cr secretion โ†‘ 0.1 mg/dL Mild effect. Stabilizes within a week.
Fenofibrate Tricor (fibrate) Increases creatinine production AND may inhibit secretion โ†‘ 0.1โ€“0.2 mg/dL Paradoxically may also have renal-protective properties in DKD.

โœ… How to Recognize Pseudo-AKI

  • Cr rises modestly (0.1โ€“0.5 mg/dL) after starting the drug
  • Rise occurs within days to 2 weeks and then stabilizes
  • Patient is clinically well โ€” no oliguria, no symptoms
  • Urine sediment is bland
  • If available, cystatin C will be unchanged (not affected by tubular secretion)
  • Cr returns to baseline on drug discontinuation

โš ๏ธ The Clinical Danger

Misinterpreting a Trimethoprim-induced Cr rise as true AKI can lead to unnecessary drug discontinuation, needless imaging, inappropriate fluid boluses, or even nephrology consultation for a non-existent problem. Conversely, assuming a Cr rise is from the drug when true AKI is occurring is equally dangerous.

Key: Pattern recognition + cystatin C confirmation when uncertain.

๐Ÿ“ The Historical Cimetidine Trick

Before modern eGFR equations, clinicians sometimes administered cimetidine prior to a timed urine collection to block tubular creatinine secretion. This made CrCl a better approximation of true GFR (since the secreted component was eliminated). While this practice is largely obsolete, it beautifully illustrates that creatinine clearance = filtration + secretion, and that blocking secretion brings CrCl closer to GFR.

โš–๏ธ Non-GFR Factors That Affect Serum Creatinine

Remember: serum creatinine at steady state = production / excretion. Anything that changes production or non-GFR excretion changes creatinine without changing GFR.

โ†‘ Increased Creatinine (Without โ†“GFR)

  • High muscle mass โ€” bodybuilders, young muscular males
  • High-meat diet โ€” particularly cooked red meat (contains creatine โ†’ creatinine)
  • Creatine supplements โ€” directly increases substrate for creatinine production
  • Drugs inhibiting secretion โ€” Trimethoprim, Cimetidine, etc. (see above)
  • Rhabdomyolysis โ€” massive release from damaged muscle (though GFR often falls too)

โ†“ Decreased Creatinine (Without โ†‘GFR)

  • Low muscle mass โ€” elderly, cachectic, amputees, paraplegia
  • Vegetarian diet โ€” less dietary creatine intake
  • Liver disease โ€” impaired creatine synthesis (creatine is made in the liver)
  • Pregnancy โ€” increased plasma volume (dilution) + increased GFR (40โ€“50%)
  • Malnutrition โ€” sarcopenia and reduced creatinine production

โš ๏ธ The Sarcopenia Trap

An elderly, frail patient with a serum creatinine of 1.0 mg/dL may have a true GFR of only 30โ€“40 mL/min. Their low muscle mass generates so little creatinine that even severe renal impairment cannot raise it above the "normal range." This is why eGFR equations incorporate age and sex โ€” but they still may overestimate GFR in cachectic patients.

Clinical pearl: Always interpret creatinine in the context of the patient's body habitus and muscle mass. A "normal" creatinine in a small, elderly patient is not reassuring.

๐Ÿ“‰ Limitations of eGFR

The estimated GFR is a regression equation derived from populations with stable kidney function. It has important limitations.

CKD-EPI 2021 Equation

  • Uses creatinine, age, and sex
  • Removed race coefficient (2021 update)
  • Most accurate for stable CKD
  • Validated for eGFR 15โ€“90 mL/min/1.73mยฒ

CKD-EPI Cystatin C (or Combined)

  • Cystatin C is not affected by muscle mass, diet, or tubular secretion
  • More accurate in extremes of body composition
  • Combined creatinine-cystatin C equation is the most accurate
  • Recommended by KDIGO when confirmatory testing is needed

When eGFR Fails โ€” Known Limitations

Limitation Explanation Solution
Non-steady state (AKI) Creatinine is changing โ€” eGFR formula assumes stability. In AKI, eGFR dramatically overestimates true GFR. Do not use eGFR in AKI. Follow Cr trends. See AKI module.
Extremes of body size Very muscular or very cachectic patients have abnormal creatinine production. Use cystatin Cโ€“based eGFR or 24-hour CrCl.
Drugs affecting Cr secretion Trimethoprim, cimetidine, dolutegravir โ†’ false โ†‘Cr โ†’ false โ†“eGFR. Recognize pattern. Confirm with cystatin C.
High-protein diet / creatine supplements Increased creatinine production โ†’ false โ†‘Cr โ†’ false โ†“eGFR. Dietary history. Cystatin C if uncertain.
Extremes of age Not well validated in very young or very elderly (>85 years). Clinical judgment. Combined equation.
Pregnancy GFR increases 40โ€“50% in pregnancy; normal values differ. eGFR equations not validated in pregnancy. Use measured CrCl.
Amputees / Paraplegia Markedly reduced muscle mass โ†’ low Cr production โ†’ falsely high eGFR. Cystatin C essential. Do not rely on creatinine-based eGFR.
Hyperfiltration High eGFR (>120) may represent early DKD, not health. Check ACR. Evaluate for hyperfiltration etiology.

โฑ๏ธ Creatinine Kinetics & the AKI Disconnect

The rate of rise of serum creatinine is disconnected from the actual GFR in AKI. This is a foundational concept covered in our AKI module. Here we expand on the why.

The Steady-State Assumption

At steady state: Creatinine production = Creatinine excretion. Serum Cr is constant. eGFR is valid.

When GFR abruptly drops (AKI), production continues at the same rate (~20 mg/kg/day from muscle), but excretion falls. Creatinine accumulates โ€” but it takes time to accumulate enough to raise serum levels.

Why 3โ€“5 Days?

Think of creatinine like filling a bathtub with a constant-rate faucet (production) and a partially closed drain (reduced GFR). The tub fills gradually, not instantly.

The time constant โ‰ˆ volume of distribution / new clearance rate. At normal body water (~42L) and severely reduced clearance, it takes ~3โ€“5 half-lives to reach a new steady state โ€” roughly 3โ€“5 days.

๐Ÿ“Š Clinical Implications Reviewed

  • Day 0 of complete renal failure: GFR = 0, but Cr may still be 1.0 mg/dL and eGFR = 90
  • Day 1: GFR = 0, Cr = 2.0, eGFR โ‰ˆ 38 โ€” still dramatically wrong
  • Day 3โ€“5: Cr finally plateaus near 8โ€“12 mg/dL and eGFR "catches up"
  • The maximum rate of rise of creatinine in anuric patients is approximately 1.0โ€“1.5 mg/dL per day (depending on muscle mass)
  • A Cr rise of only 0.3 mg/dL in 48 hours (KDIGO Stage 1) may represent a massive GFR drop
  • Declining Cr after AKI does NOT mean GFR has normalized โ€” it means creatinine is being cleared faster than it is being produced, but the system may not yet be at steady state

๐Ÿ“Š BUN/Creatinine Ratio โ€” Context Matters

BUN (blood urea nitrogen) and creatinine are both markers of kidney function, but they are handled differently by the kidney:

Creatinine

  • Freely filtered + secreted
  • Not significantly reabsorbed
  • Production relatively constant

BUN (Urea)

  • Freely filtered
  • Significantly reabsorbed (40โ€“60%), especially in volume-depleted states under ADH influence
  • Production varies with protein intake, GI bleeding, steroids, catabolic states
BUN/Cr Ratio Interpretation Common Causes
10:1 โ€“ 20:1 Normal Normal renal function
>20:1 Prerenal pattern (BUN rises disproportionately) Volume depletion, CHF, GI bleed, high-protein diet, steroids, catabolic states
<10:1 Intrinsic renal damage or decreased urea production ATN, rhabdomyolysis (Cr disproportionately elevated), liver failure (low BUN production), low-protein diet

๐Ÿงช Cystatin C โ€” The Creatinine Complement

When creatinine cannot be trusted, cystatin C provides an independent GFR estimate.

โœ… Advantages

  • Produced by all nucleated cells at a constant rate
  • Not affected by muscle mass, diet, or sex
  • Not significantly secreted by tubules
  • Freely filtered at the glomerulus
  • Combined Cr-CysC equation is most accurate eGFR

โš ๏ธ Limitations

  • Affected by high-dose corticosteroids (โ†‘ production)
  • Thyroid dysfunction: hyperthyroid โ†‘, hypothyroid โ†“ cystatin C
  • Obesity and inflammation may affect levels
  • More expensive and less widely available than creatinine
  • Still has the same steady-state requirement for eGFR

๐ŸŽฏ When to Order Cystatin C

  • Suspected drug-induced creatinine elevation (trimethoprim, dolutegravir)
  • Extremes of body composition (amputees, bodybuilders, cachectic patients)
  • eGFR near critical decision thresholds (e.g., 15 mL/min for dialysis planning, 45 for referral)
  • Discrepancy between creatinine-based eGFR and clinical assessment
  • KDIGO recommends confirmatory cystatin C testing when eGFR 45โ€“59 without other markers of kidney damage

๐Ÿ… Measured GFR โ€” The Gold Standard

Measured GFR (mGFR) using exogenous filtration markers provides the most accurate assessment. The ideal marker is freely filtered, not reabsorbed, not secreted, not metabolized, and not protein-bound.

Inulin Clearance

Historical gold standard. Fructose polymer meeting all ideal filtration marker criteria. Requires continuous IV infusion, timed urine collections, and multiple blood samples โ€” impractical for routine use.

Iohexol Plasma Clearance

Non-ionic, non-radioactive contrast agent. Single injection + plasma sampling. Excellent correlation with inulin. Preferred in many centers. Used in the landmark Stockholm cohort studies.

Nuclear Medicine (โนโนแตTc-DTPA, โตยนCr-EDTA)

Radioactive markers with similar accuracy. ยนยฒโตI-iothalamate used in many US research centers. Avoid timed urine collections with plasma clearance techniques.

When to consider measured GFR: Living kidney donor evaluation, when both eGFRcr and eGFRcys are unreliable (e.g., cirrhosis), research protocols, or critical clinical decisions (transplant evaluation, questionable dialysis timing).

๐Ÿ“œ Evolution of Creatinine-Based eGFR Equations

Understanding the evolution of equations helps appreciate their limitations and appropriate application.

Equation Year Variables Limitations Status
Cockcroft-Gault 1976 Age, weight, sex, Cr Estimates CrCl (not GFR). Not standardized to BSA. Overestimates in obesity. Largely replaced
MDRD 1999 Age, sex, race, Cr Developed in CKD population. Systematically underestimates GFR >60. Race coefficient. Replaced
CKD-EPI 2009 2009 Age, sex, race, Cr Improved accuracy at higher GFR. Still included race coefficient. Replaced
CKD-EPI 2021 2021 Age, sex, Cr Race-free. Now standard for clinical reporting. ~87โ€“88% P30 accuracy. Current Standard
CKD-EPI 2012 CysC 2012 Age, sex, Cystatin C Race-free. More accurate in extremes of body composition. Affected by steroids, thyroid, inflammation. Confirmatory
CKD-EPI 2021 Cr-CysC 2021 Age, sex, Cr, Cystatin C Race-free. ~91โ€“92% P30 accuracy. Most accurate available equation. Most Accurate
The "Creatinine-Blind" Range: The inverse, nonlinear relationship between Cr and GFR means a serum Cr of 1.0 mg/dL may represent a GFR of 120 in a young muscular male or 50 in an elderly sarcopenic female. Patients can lose >50% of kidney function before creatinine rises above the "normal" reference range. Always report and interpret eGFR โ€” never creatinine alone.

๐Ÿ“Š Comprehensive: What Makes eGFR Wrong?

Beyond the basics covered above, here are systematic tables of all conditions that cause eGFRcr and eGFRcys to deviate from measured GFR.

Conditions Where eGFRcr OVERESTIMATES True GFR (Falsely Reassuring)

Condition Mechanism Clinical Significance
Sarcopenia / Low muscle massโ†“Cr generationCommon in elderly, chronic illness; may mask CKD
Cachexia / WastingSevere โ†“muscle massCancer, HF, COPD; significantly overestimates GFR
AmputationsProportional loss of muscleCystatin C essential for accurate assessment
Paraplegia / QuadriplegiaAtrophy and denervationMay have very low Cr despite significant CKD
Advanced cirrhosisโ†“Hepatic creatine synthesis + muscle wasting + โ†‘tubular secretioneGFRcr very unreliable; use CysC or measured GFR
Vegetarian / Low-protein dietโ†“Dietary creatineMay lower Cr by 10โ€“15%
Advanced CKD (GFR <15โ€“20)โ†‘โ†‘Tubular secretion (up to 50% of excretion); extrarenal clearance via gut creatininaseeGFRcr may overestimate true GFR by 20โ€“30% in Stage 5
Pregnancyโ†‘GFR, โ†‘plasma volume, โ†‘tubular secretionEquations not validated; use measured CrCl

Conditions Where eGFRcr UNDERESTIMATES True GFR (Falsely Alarming)

Condition Mechanism Clinical Significance
High muscle mass / Bodybuildersโ†‘Cr generationMay appear to have CKD when GFR is normal
High dietary meat intakeExogenous Cr from cooked meatAcute Cr increase post-meal
Creatine supplementsDirect Cr precursorCommon in athletes
Trimethoprim, Cimetidine, Cobicistat, Dolutegravir, DronedaroneInhibit OCT2/MATE tubular secretionReversible; establish new baseline after 2โ€“4 weeks
Fenofibrateโ†‘Cr production + โ†“secretionReversible; may also be nephroprotective
Jaffe assay interferenceChromogens (bilirubin, ketones) react with picrateUse enzymatic assay for specificity
DKAAcetoacetate interferes with Jaffe reactionFalsely โ†‘Cr during DKA; resolves with treatment
Acute rhabdomyolysisMassive Cr release from damaged muscleCr may rise before AKI develops

Factors Affecting Cystatin Cโ€“Based eGFR

eGFRcys UNDERESTIMATES GFR (โ†‘CysC)

  • Hyperthyroidism โ€” โ†‘cellular metabolic rate (62% have elevated CysC)
  • Glucocorticoids โ€” stimulate CysC gene expression (dose-dependent)
  • Obesity (Class IIโ€“III) โ€” โ†‘production from adipose + inflammation
  • Systemic inflammation / High CRP โ€” sepsis, autoimmune disease
  • Malignancy โ€” โ†‘cell turnover (especially hematologic)
  • HIV (uncontrolled) โ€” immune activation
  • Smoking, diabetes, heart failure โ€” chronic low-grade inflammation

eGFRcys OVERESTIMATES GFR (โ†“CysC)

  • Hypothyroidism โ€” โ†“cellular production (eGFRcys โ†‘ when treated)
  • Some immunosuppressive therapy โ€” variable effect
  • Much fewer confounders than Cr in this direction

๐Ÿ“ˆ The eGFRcys / eGFRcr Ratio โ€” Beyond GFR Estimation

When both markers are measured, their ratio provides diagnostic and prognostic information beyond either marker alone. A ratio <0.7 independently predicts mortality.

Ratio Interpretation Possible Causes Action
>1.0โ€“1.15eGFRcys higher than eGFRcrHigh muscle mass, meat intake, creatine supplements, TMP, hypothyroidismeGFRcys may be more accurate; evaluate confounders
0.85โ€“1.0Normal concordanceNeither marker disproportionately affectedEither eGFR likely reliable; eGFRcr-cys for best accuracy
0.70โ€“0.84Mild discordance (eGFRcys lower)Mild sarcopenia, low-dose steroids, subclinical inflammationAssess for sarcopenia; use eGFRcr-cys
<0.70Marked discordanceSarcopenia, steroids, hyperthyroidism, malignancy, Shrunken Pore SyndromeEvaluate confounders; if absent โ†’ consider SPS; โ†‘mortality risk
<0.60Severe discordanceShrunken Pore Syndrome most likely if confounders excludedHigh mortality risk independent of GFR; close cardiovascular monitoring

๐Ÿ”ฌ Shrunken Pore Syndrome

First described in 2015, SPS is defined by an eGFRcys/eGFRcr ratio below 0.60โ€“0.70 in the absence of known confounders (steroids, sarcopenia). The syndrome reflects selective impairment of filtration of mid-sized molecules (10โ€“30 kDa, including cystatin C at 13 kDa) while preserving filtration of smaller molecules (creatinine at 113 Da).

SPS is associated with hazard ratios of 3.0โ€“7.3 for mortality depending on the population studied. The 2024 KDIGO guidelines recommend measuring both markers; the ratio adds prognostic information beyond GFR alone.

๐Ÿ’ก Prognostic Value Beyond GFR Accuracy

The CKD Prognosis Consortium meta-analysis (JAMA 2025) showed individuals with eGFRcys at least 30% lower than eGFRcr had significantly higher risks of all-cause mortality, cardiovascular mortality, heart failure hospitalization, and kidney failure โ€” even after adjusting for eGFRcr and albuminuria. The ratio captures cardiovascular/metabolic health information beyond filtration function.

๐ŸŽฏ When Markers Disagree: Which Is Closer to Truth?

Evidence from the Stockholm Iohexol Cohort (Fu et al., JASN 2023)

6,185 adults with 9,404 concurrent measurements of creatinine, cystatin C, and iohexol plasma clearance โ€” including patients with CVD, HF, diabetes, liver disease, and cancer.

Key Finding: When eGFRcys < eGFRcr, Creatinine Has the Larger Error

In the 47% of samples where eGFRcys was >20% lower than eGFRcr (the common cardiorenal pattern):

  • Creatinine overestimated true GFR by +15.0 mL/min/1.73mยฒ
  • Cystatin C underestimated by only โˆ’8.5 mL/min/1.73mยฒ
  • Combined equation (eGFRcr-cys) bias: only +0.8 mL/min/1.73mยฒ

Creatinine's error was nearly TWICE the magnitude of cystatin C's error.

Performance Metrics by Discordance Pattern

Metric eGFRcys < eGFRcr (47%) eGFRcys โ‰ˆ eGFRcr (45%) eGFRcys > eGFRcr (8%)
Median mGFR (iohexol)477174
Median eGFRcr62 (overestimates)7367
Median eGFRcys387183
Median eGFRcr-cys49 (closest to 47)7275
eGFRcr Bias (eGFR โˆ’ mGFR)+15.0+3.0โˆ’4.5
eGFRcys Biasโˆ’8.5โˆ’2.0+8.4
eGFRcr-cys Bias+0.8+0.5+1.4
P30 (eGFRcr)50%88%70%
P30 (eGFRcys)73%89%66%
P30 (eGFRcr-cys)84%93%84%
Correct CKD Stage (eGFRcr)38%68%61%
Correct CKD Stage (eGFRcr-cys)62%74%72%

P30 = proportion of estimates within 30% of measured GFR. Bias = median (eGFR โˆ’ mGFR) in mL/min/1.73mยฒ. Data: Fu et al., JASN 2023.

Why Creatinine Overestimates in Cardiorenal Patients

In HF, diabetes with complications, cancer, and advanced age, muscle mass is frequently reduced (sarcopenia, cardiac cachexia). Less muscle โ†’ less creatinine โ†’ equations interpret low Cr as preserved GFR. The patient has both reduced muscle mass AND reduced kidney function.

The Reframing

When eGFRcys is substantially lower than eGFRcr in a cardiorenal patient, do not assume cystatin C is wrong. mGFR-validated data shows creatinine is typically further from truth. Use eGFRcr-cys. The patient likely has more kidney disease than creatinine suggests.

Clinical Implication: Relying on eGFRcr alone in patients with HF, diabetes, cancer, or sarcopenia may substantially overestimate kidney function โ€” delaying CKD recognition, resulting in inappropriate drug dosing, or missing eligibility for renal-protective therapies. Always obtain cystatin C and calculate eGFRcr-cys in these populations.

๐Ÿ“‰ Creatinine Sensitivity at Low GFR: The Advanced CKD Paradox

In patients with GFR below 20 mL/min/1.73mยฒ, several factors cause creatinine-based equations to systematically overestimate true GFR:

  • โ†‘Tubular secretion โ€” accounts for up to 50% of urinary creatinine excretion in advanced CKD (vs. 10โ€“15% at normal GFR)
  • Extrarenal clearance โ€” gut bacterial creatininase becomes clinically significant
  • Sarcopenia and cachexia โ€” common in advanced CKD, reducing creatinine generation
Clinical impact: In patients with eGFR <20, creatinine-based equations may overestimate true GFR by 20โ€“30%. When accurate GFR is needed for dialysis initiation timing or transplant evaluation, use eGFRcr-cys or measured GFR.

๐Ÿ‘ฅ Special Populations

Elderly Patients

Age-related sarcopenia reduces Cr generation โ†’ eGFRcr overestimates. Combined with age-related GFR decline, this masks significant CKD. eGFRcr-cys is preferred when accuracy matters.

Cirrhosis

โ†“Hepatic creatine synthesis + muscle wasting + โ†‘tubular secretion โ†’ eGFRcr markedly overestimates. CysC performs better but may be affected by inflammation. Measured GFR with iohexol recommended for liver transplant evaluation.

Kidney Transplant Recipients

Altered Cr metabolism from immunosuppressants + prior chronic illness muscle loss. CysC may be affected by glucocorticoids early post-transplant. Combined equation preferred; interpret trends over time.

Acute Kidney Injury

Neither Cr nor CysC equations are validated in AKI. Both lag behind true GFR changes. Interpret absolute values and trends โ€” not calculated eGFR. See our AKI module.

๐Ÿ’ฐ Cystatin C: Cost, Availability & Coverage

Laboratory Costs

  • CysC reagent: ~$5โ€“10/test
  • Creatinine reagent: ~$0.50/test
  • Cost differential decreasing with โ†‘test volumes

Medicare Coverage (CPT 82610)

  • Reimbursement: ~$18.52/test
  • Requires documentation of medical necessity
  • Coverage criteria: uncertain eGFRcr range, known Cr confounders, or management impact
Tip for coverage: Document in the order why creatinine-based eGFR may be inaccurate (sarcopenia, extremes of muscle mass, cirrhosis, medication effects) and how accurate GFR will affect management (drug dosing, CKD staging, transplant evaluation, eligibility for renal-protective therapies).

๐Ÿงญ Clinical Approach to GFR Assessment

  1. Start with eGFRcr (CKD-EPI 2021) โ€” appropriate for routine monitoring in stable patients without known confounders.
  2. Add cystatin C (calculate eGFRcr-cys) when: eGFRcr is near decision thresholds (60, 45, 30, 15), Cr reliability is in question (sarcopenia, cirrhosis, drug effects), clinical findings are discordant with eGFRcr, or accurate GFR is needed for drug dosing.
  3. Calculate the eGFRcys/eGFRcr ratio when both markers are available. Ratio <0.7 warrants investigation for sarcopenia, steroid use, or Shrunken Pore Syndrome, and conveys independent prognostic information.
  4. Consider measured GFR (iohexol/iothalamate clearance) for living kidney donor evaluation, when both eGFR markers are unreliable, or when the highest accuracy is required.
  5. Always interpret in clinical context. 80โ€“90% of eGFR values fall within 30% of measured GFR โ€” meaning 10โ€“20% of patients will have significant discrepancies. No equation is infallible.

๐Ÿ“‹ High-Yield Summary: Most vs. Some

MOST Changes in Cr = GFR Changes

  • AKI (prerenal, intrinsic, postrenal)
  • CKD progression
  • Hemodynamic changes (ACEi/ARB, NSAIDs, SGLT2i)
  • Volume depletion / overload
  • Sepsis, cardiorenal syndrome

โ†’ These are true GFR changes and warrant clinical action.

SOME Changes in Cr โ‰  GFR Changes

  • Drugs blocking Cr secretion (TMP, cimetidine, dolutegravir, triamterene)
  • Changes in muscle mass / diet
  • Creatine supplements
  • Rhabdomyolysis (massive Cr release from muscle)
  • Lab interference (e.g., high bilirubin, ketoacidosis with Jaffe assay)

โ†’ These are "pseudo" changes. Use cystatin C, clinical context, and drug history to differentiate.

๐ŸŽ“ Key Learning Points

  1. GFR is determined by Kf ร— (PGC โˆ’ PBS โˆ’ ฯ€GC). Afferent and efferent arteriolar tone are the principal regulators of PGC.
  2. Creatinine is handled three ways: filtered (~85โ€“90%), secreted (~10โ€“15% via OCT2/MATE), and minimally reabsorbed.
  3. Because of secretion, CrCl overestimates GFR โ€” this error grows as GFR falls (up to 50% of Cr excretion via secretion in Stage 5 CKD).
  4. Multiple drugs (trimethoprim, cimetidine, triamterene, dolutegravir, cobicistat, dronedarone) raise creatinine by blocking tubular secretion, not by reducing GFR.
  5. Muscle mass, diet, and supplements alter creatinine production independent of GFR. A "normal" creatinine in a sarcopenic patient may mask severe CKD.
  6. eGFR assumes steady state โ€” it is invalid in AKI, where the rate of rise of Cr is disconnected from the actual GFR.
  7. The CKD-EPI 2021 race-free equation is the current standard. The combined eGFRcr-cys equation is the most accurate (~91โ€“92% P30).
  8. Cystatin C provides an independent GFR estimate. When eGFRcys < eGFRcr in cardiorenal patients, creatinine is typically further from truth than cystatin C (Stockholm cohort).
  9. The eGFRcys/eGFRcr ratio <0.7 independently predicts mortality, even after adjusting for eGFR and albuminuria.
  10. Hyperfiltration (elevated PGC) drives early DKD โ€” ACEi/ARBs and SGLT2 inhibitors are nephroprotective because they reduce PGC.
  11. The "Triple Whammy" (NSAID + ACEi/ARB + diuretic) is a predictable hemodynamic catastrophe.
  12. Most changes in creatinine reflect GFR changes โ€” but the clinician must recognize the exceptions.

๐Ÿ“š References

  1. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. PubMed
  2. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473-2483. PubMed
  3. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. PubMed
  4. Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021;32(12):2994. PubMed
  5. Levey AS, Coresh J, Tighiouart H, et al. Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol. 2020;16(1):51-64. PubMed
  6. Soveri I, Berg UB, Bjรถrk J, et al. Measuring GFR: a systematic review. Am J Kidney Dis. 2014;64(3):411-424. PubMed
  7. Shlipak MG, Matsushita K, ร„rnlรถv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932. PubMed
  8. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29. PubMed
  9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117. PubMed
  10. Grubb A, Lindstrรถm V, Jonsson M, et al. Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: 'Shrunken pore syndrome'. Scand J Clin Lab Invest. 2015;75(4):333-340. PubMed
  11. Purde MT, Nock S, Risch L, et al. Ratio of cystatin C and creatinine-based estimates of the glomerular filtration rate predicts mortality in healthy seniors independent of kidney function. Scand J Clin Lab Invest. 2016;76(4):341-343. PubMed
  12. Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28(5):830-838. PubMed
  13. Delanaye P, Cavalier E, Pottel H. Serum Creatinine: Not So Simple!. Nephron. 2017;136(4):302-308. PubMed
  14. Fu EL, Levey AS, Coresh J, et al. Accuracy of GFR Estimating Equations in Patients with Discordances between Creatinine and Cystatin C-Based Estimations. J Am Soc Nephrol. 2023;34(7):1241-1251. PubMed
  15. Estrella MM, Ballew SH, Sang Y, et al. Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis. JAMA. 2025;334(21):1915. PubMed
  16. Heerspink HJL, Stefรกnsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436. PubMed
  17. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117. PubMed
  18. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens. 2001;10(1):89-98. PubMed
  19. Yu ASL, Chertow GM, Luyckx VA, et al., eds. Brenner & Rectorโ€™s The Kidney. 11th ed. Elsevier; 2020. Publisher.
  20. Francoz C, Glotz D, Moreau R, et al. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52(4):605-613. PubMed
  21. Pinsino A, Carey MR, Husain S, et al. The Difference Between Cystatin C- and Creatinine-Based Estimated GFR in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF. Am J Kidney Dis. 2023;82(5):521-533. PubMed

๐Ÿ”— Related Lectures & Resources

๐Ÿ“š For Educational Purposes Only

ยฉ 2025 Andrew Bland MD - All Rights Reserved